Compare STTK & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STTK | NPCE |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.4M | 432.3M |
| IPO Year | 2020 | 2021 |
| Metric | STTK | NPCE |
|---|---|---|
| Price | $6.95 | $14.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $7.60 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 502.9K | 185.7K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | 29.03 |
| EPS | N/A | ★ N/A |
| Revenue | $1,000,000.00 | ★ $99,986,000.00 |
| Revenue This Year | N/A | $0.90 |
| Revenue Next Year | N/A | $24.46 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.13 |
| 52 Week Low | $0.71 | $7.56 |
| 52 Week High | $7.68 | $18.97 |
| Indicator | STTK | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 65.29 | 51.64 |
| Support Level | $5.75 | $14.02 |
| Resistance Level | N/A | $14.72 |
| Average True Range (ATR) | 0.47 | 0.65 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 61.66 | 64.16 |
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.